Does adherence to lipid-lowering medications improve cancer survival? A nationwide study of breast and colorectal cancer, and melanoma

Cohort study (total n=38,195) found that each 10% increase in 1-year adherence to lipid-lowering medications was associated with reduced cancer specific mortality (HR 0.92, 95%CI 0.91-0.93 for breast cancer, 0.92, 0.91-0.93 for colorectal cancer and 0.97, 0.94-1.00 for melanoma).

British Journal of Clinical Pharmacology